Posted inClinical Updates Hematology-Oncology Oncology
Innovative CD20-Directed Autologous CAR T-Cell Therapy for Treatment-Refractory Waldenström Macroglobulinemia
This study demonstrates the promising safety and efficacy of CD20-targeted autologous CAR T-cell therapy in BTKi-refractory Waldenström macroglobulinemia, showing an 80% deep response rate and warranting further investigation in larger trials.